Article Sidebar

Submitted
Jul 26, 2023
Accepted
Aug 29, 2023
Published
Oct 1, 2023
Download
PDF
Statistic
Read Counter : 236 Download : 425

Main Article Content

Abstract

Background: Therapy in chronic kidney disease aims to slow down the prognosis of the disease. Objectives: Describe the types of classes and names of most drugs in treating chronic kidney disease patients based on the stage of the disease. As well as analysing the use of renal risk drugs in patients with chronic kidney disease. Material and Methods: This descriptive research will be carried out in May-June 2023. The population of this study was the entire medical record of inpatient chronic kidney disease patients at Ansari Saleh Hospital. Data analysis was performed uni variat for the study of patient characteristics and therapy profiles, while the analysis of the use of renal risk medications refers to the 2019 renal handbook. Results: A total of 51 medical records were analysed. The top five drug classes based on stages 4 and 5 include diuretics, cephalosporin antibiotics, vitamins, trace elements, angiotensin II receptor blockers, and insulin. The top five drugs received by patients based on disease stages 4 and 5 consist of furosemide, ceftriaxone, aminefron®, candesartan, and insulin aspart. Renal risk drugs found in studies include drugs that need dose adjustment, are lisinopril, ramipril, cefixime, cefotaxime, meropenem, levofloxacin, ciprofloxacin, bisoprolol, diltiazem, and simvastatin. At the same time, renal-risk drugs that need to be avoided are hydrochlorothiazide and spironolactone. Conclusions: Furosemide diuretics are the most widely used therapy in stages 4 and 5. Hospitalised chronic kidney disease patients receive some renal risk drugs that, in the literature, need dose adjustment, and some need to be avoided.

Keywords

Chronic Kidney Disease Renal-risk drugs Therapeutic Profile

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Sari, O. M., Putra, A. M. P., Azizah, P. N., & Sofia, S. (2023). Therapy Profile and Drug Use Analysis of Chronic Kidney Disease Patients Hospitalized at Dr. H. M. Ansari Saleh Hospital: Profil Terapi dan Analisis Penggunaan Obat Pasien Chronic Kidney Disease Rawat Inap Rumah Sakit dr. H. M. Ansari Saleh. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 9(2), 233-246. https://doi.org/10.22487/j24428744.2023.v9.i2.16488

References

  1. Andriani, S., Rahmawati, F., & Andayani, T. M. (2021). Penyesuaian Dosis Obat pada Pasien Gagal Ginjal Kronis Rawat Inap di Rumah Sakit Kabupaten Tegal, Indonesia. Majalah Farmaseutik, 17(1), 46. https://doi.org/10.22146/farmaseutik.v17i1.48683
  2. Ashley, C., & Dunleavey, A. (2019). The renal drug handbook : the ultimate prescribing guide for renal practitioners (5th ed.). London: CRC Press.
  3. Bello, A. K., Alrukhaimi, M., Ashuntantang, G. E., Basnet, S., Rotter, R. C., Douthat, W. G., … Moe, O. (2017, October 1). Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney International Supplements, Vol. 7, pp. 122–129. Elsevier B.V. https://doi.org/10.1016/j.kisu.2017.07.007
  4. Chakraborty, S., Ghosh, S., Banerjea, A., De, R., Hazra, A., & Mandal, S. (2016). Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis. Indian Journal of Pharmacology, 48(5). https://doi.org/10.4103/0253-7613.190760
  5. Chen, T. K., Knicely, D. H., & Grams, M. E. (2019, October 1). Chronic Kidney Disease Diagnosis and Management: A Review. JAMA - Journal of the American Medical Association, Vol. 322, pp. 1294–1304. American Medical Association. https://doi.org/10.1001/jama.2019.14745
  6. Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., … Mann, J. F. E. (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 99(3), S1–S87. https://doi.org/10.1016/j.kint.2020.11.003
  7. Chua, D., Lo, A., & Lo, C. (2010). Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe? Clinical Cardiology, 33(10), 604–608. https://doi.org/10.1002/clc.20838
  8. Deskur-Śmielecka, E., Chudek, J., Neumann-Podczaska, A., Mossakowska, M., Wizner, B., & Wieczorowska-Tobis, K. (2019). Use of renal risk drugs in a nation-wide Polish older adult population: an analysis of PolSenior database. BMC Geriatrics, 19(1). https://doi.org/10.1186/s12877-019-1075-5
  9. DiPiro, J. T. (2020). Pharmacotherapy A Pathophysiologic Approach Tenth Edition. In McGraw-Hill Education (Vol. 5).
  10. Guedes, M., Robinson, B. M., Obrador, G., Tong, A., Pisoni, R. L., & Pecoits-Filho, R. (2020). Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives. Kidney360, 1(8), 855–862. Lippincott Williams and Wilkins. https://doi.org/10.34067/KID.0001442020
  11. Hahr, A. J., & Molitch, M. E. (2015). Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology, 1(1). https://doi.org/10.1186/s40842-015-0001-9
  12. Hebert, S. A., & Ibrahim, H. N. (2022). Hypertension Management in Patients with Chronic Kidney Disease. Methodist DeBakey Cardiovasc J, 18(4), 41–49. https://doi.org/10.14797/m
  13. Juanita Pakingki, P., Mongi, J., Maarisit, W., & Z S Karundeng, E. Z. (n.d.). Pola Peresepan Penyakit Gagal Ginjal Di Instalasi Rawat Inap Rs. Gunung Maria Tomohon. Jurnal Biofarmasetikal Tropis, 2019(2), 109–119.
  14. Kassa Birarra, M., Mekonnen, G. B., Gelayee, D. A., Assimamaw, N. T., & Kifle, Z. D. (2022). Drug dose adjustment in patients with renal impairment attending a specialized referral hospital, Northwest Ethiopia. Metabolism Open, 16, 100211. https://doi.org/10.1016/j.metop.2022.100211
  15. Kementerian Kesehatan Republik Indonesia. (2019). Laporan Nasional Riskesdas 2018. Jakarta.
  16. Luyckx, V. A., Al-Aly, Z., Bello, A. K., Bellorin-Font, E., Carlini, R. G., Fabian, J., … Stanifer, J. (2021, January 1). Sustainable Development Goals relevant to kidney health: an update on progress. Nature Reviews Nephrology, Vol. 17, pp. 15–32. Nature Research. https://doi.org/10.1038/s41581-020-00363-6
  17. Luyckx, V. A., Tonelli, M., & Stanifer, J. W. (2018). The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization, 96(6), 414-422C. https://doi.org/10.2471/BLT.17.206441
  18. Mallappallil, M., Friedman, E. A., Delano, B. G., Mcfarlane, S. I., & Salifu, M. O. (2014, September 1). Chronic kidney disease in the elderly: Evaluation and management. Clinical Practice, Vol. 11, pp. 525–535. Future Medicine Ltd. https://doi.org/10.2217/cpr.14.46
  19. Mohd Shariff, N., Shah, S. A., & Kamaludin, F. (2017). Faktor Penghalang dan Penggalak Kepatuhan daripada Perspektif Pesakit Tuberkulosis Cicir Rawatan di Kuala Lumpur. Jurnal Sains Kesihatan Malaysia, 15(1), 75–87. https://doi.org/10.17576/jskm-2017-1501-10
  20. National Institute for Health and Care Excellence. (2019). Sodium zirconium cyclosilicate for treating hyperkalaemia. Retrieved from www.nice.org.uk/guidance/ta599
  21. Nori, L. S., Srikartika, V. M., & Intannia, D. (2015). Profil dan Evaluasi Terapi Anemia pada Pasien Gagal Ginjal Kronik yang Menjalani Hemodialisa di BLUD RS Ratu Zalecha Martapura Periode Juli-Oktober 2014. Jurnal Pharmascience, 2(1), 65–71.
  22. Reilly Lukela, J., Medicine, G., Van Harrison, R., Jimbo, M., Mahallati, A., Sy, A. Z., & Rew, K. T. (2019). Quality Department Guidelines for Clinical Care Ambulatory Chronic Kidney Disease Guideline Team Team Leader Ambulatory Clinical Guidelines Oversight. Retrieved from http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm
  23. Santos-Díaz, G., Pérez-Pico, A. M., Suárez-Santisteban, M. Á., García-Bernalt, V., Mayordomo, R., & Dorado, P. (2020). Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a spanish hospital. Pharmaceutics, 12(8), 1–11. https://doi.org/10.3390/pharmaceutics12080713
  24. Tuloli, T. S., Madania, Mustapa, M. A., & Tuli, E. P. (2019). Evaluasi Penggunaan Obat Pada Pasien Gagal Ginjal Kronik Yang Menjalani Hemodialisis di RSUD Toto Kabila Periode 2017-2018. Parapemikir, 8(2), 25–32.
  25. Vassalotti, J. A., Centor, R., Turner, B. J., Greer, R. C., Choi, M., & Sequist, T. D. (2016, February 1). Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. American Journal of Medicine, Vol. 129, pp. 153-162.e7. Elsevier Inc. https://doi.org/10.1016/j.amjmed.2015.08.025
  26. Wu, C. H., Yang, Y. W., Hung, S. C., Kuo, K. L., Wu, K. D., Wu, V. C., & Hsieh, T. C. (2017). Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease. PLoS ONE, 12(5). https://doi.org/10.1371/journal.pone.0176847
  27. Yamanoglu, N. G. C., & Yamanoglu, A. (2022). The effect of calcium gluconate in the treatment of hyperkalemia. Turkish Journal of Emergency Medicine, 22(2), 75–82. https://doi.org/10.4103/2452-2473.342812
  28. Yu, M. Y., Yeo, J. H., Park, J. S., Lee, C. H., & Kim, G. H. (2017). Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS ONE, 12(3). https://doi.org/10.1371/journal.pone.0173542
  29. Yusri, Y. F., Amalia, L., & Lisni, I. (2018). Studi Penggunaan Obat Untuk Menangani Gangguan Natrium dan Kalium Pasien Penyakit Ginjal Terminal di RS Muhammadiyah Bandung. Jurnal Sains Farmasi & Klinis, 5(3), 233–242.